Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives
Open Access
- 24 October 2018
- journal article
- review article
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 3 (1) , 24-33
Abstract
Neoadjuvant chemoradiotherapy (nCRT) has been widely used as a multidisciplinary approach for stage II/III rectal cancer. However, its safety and efficacy are controversial because previous studies have shown conflicting outcomes. The present review aimed to elucidate the benefits and limitations of nCRT for patients with rectal cancer. Future perspectives of nCRT are also described. No recent randomized trials have been able to show a survival benefit, although many studies have demonstrated good local control with the use of fluoropyrimidine (e.g. 5‐fluorouracil [FU] or capecitabine)‐based nCRT. Addition of oxaliplatin (OX) to FU‐based nCRT might improve overall survival by preventing distant metastasis, as shown in recent meta‐analyses. However, control of adverse effects is an important concern with this treatment. New treatment strategies such as nonoperative management (watch and wait policy) and total neoadjuvant therapy (TNT) are promising, but the establishment of reliable diagnostic methods of metastasis is essential. Development of new biomarkers is also necessary to select patients who are more likely to benefit from nCRT.Keywords
This publication has 101 references indexed in Scilit:
- Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal AdenocarcinomaAnnals of Surgical Oncology, 2013
- Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal CancerJournal of Clinical Oncology, 2012
- P53 Status as a Predictive Biomarker for Patients Receiving Neoadjuvant Radiation-Based Treatment: A Meta-Analysis in Rectal CancerPLOS ONE, 2012
- Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trialThe Lancet Oncology, 2012
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal CancerJournal of Clinical Oncology, 2012
- Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III TrialJournal of Clinical Oncology, 2011
- Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancerCancer, 2011
- Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2Journal of Clinical Oncology, 2010
- Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03Journal of Clinical Oncology, 2009
- Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation TherapyAnnals of Surgery, 2004